Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Ben Buelow"'
Autor:
Ryan Jacobs, Ranjit Nair, Seok-Goo Cho, Sumana Devata, Sameh Gaballa, Dok Hyun Yoon, Don Stevens, Jin Seok Kim, Nirav N Shah, Denise Marie Brennan, Jason Law, Robin Lesley, Rob Chen, Alessandra Forcina, Ben Buelow, Jing-Zhou Hou
Publikováno v:
HemaSphere, Vol 7, p e60614fc (2023)
Externí odkaz:
https://doaj.org/article/89b6f6d3e96a4eb59ded576b91f97b35
Autor:
Brian C. Avanzino, Kirthana Prabhakar, Pranjali Dalvi, Sharon Hartstein, Hannes Kehm, Aarti Balasubramani, Andrew A. Boudreau, Ben Buelow, Karen Chang, Laura M. Davison, Suhasini Iyer, Vidyut Kalwit, Kristin Lewis Wilson, Harbani K. Malik-Chaudhry, Will Pierson, Geovanni Pineda, Udaya S. Rangaswamy, Sowmya Saiganesh, Ute Schellenberger, Harshad S. Ugamraj, Rodolfovan D. Yabut, Roland Buelow, Jocelyn Chapman, Nathan D. Trinklein, Katherine E. Harris
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
The use of T-cell engagers (TCEs) to treat solid tumors is challenging, and several have been limited by narrow therapeutic windows due to substantial on-target, off-tumor toxicities due to the expression of low levels of target antigens on healthy t
Externí odkaz:
https://doaj.org/article/9e96f15bb0a54d7bb137adf3be604c3c
Autor:
David M. Foureau, Manisha Bhutani, Myra Robinson, Fei Guo, Duy Pham, Ben Buelow, Nury Steuerwald, Katherine Rigby, Elise Tjaden, Marina Leonidas, Barry A. Paul, Shebli Atrash, Ami Ndiaye, James T. Symanowski, Peter M. Voorhees, Saad Z. Usmani
Publikováno v:
eJHaem, Vol 1, Iss 1, Pp 113-121 (2020)
Abstract TNB‐383B is a fully human BCMA‐targeting T‐cell engaging bispecific monoclonal antibody (T‐BsAb). We assessed ex vivo efficacy of this drug to mediate killing of bone marrow mononuclear cells (BMMCs) freshly isolated from 10 patients
Externí odkaz:
https://doaj.org/article/9eb554299b834585993fcebfa249976e
Autor:
Lawrence Fong, Serena Kwek, Rong Deng, Yuping Li, Kevin Dang, Giulia Castello, Starlynn C Clarke, Aarti Balasubramani, Andrew Boudreau, Laura Davison, Katherine E Harris, Duy Pham, Preethi Sankaran, Harshad S Ugamraj, Alec Starzinski, Suhasini Iyer, Wim van Schooten, Ute Schellenberger, Wenchao Sun, Nathan D Trinklein, Roland Buelow, Ben Buelow, Pranjali Dalvi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Background Therapeutic options currently available for metastatic castration-resistant prostate cancer (mCRPC) do not extend median overall survival >6 months. Therefore, the development of novel and effective therapies for mCRPC represents an urgent
Externí odkaz:
https://doaj.org/article/b008929f34b84d778350eb4e4a7bcce4
Publikováno v:
PLoS ONE, Vol 4, Iss 7, p e6339 (2009)
Poly adenosine diphosphate-ribose polymerase-1 (PARP-1) is a multifunctional enzyme that is involved in two major cellular responses to oxidative and nitrosative (O/N) stress: detection and response to DNA damage via formation of protein-bound poly a
Externí odkaz:
https://doaj.org/article/0538f7f3666340658c92f9b335d5230c
Autor:
Ben Buelow, Andrew M Scharenberg
Publikováno v:
PLoS ONE, Vol 3, Iss 9, p e3264 (2008)
Conditional gene targeting using the Cre-loxp system is a well established technique in numerous in vitro and in vivo systems. Ligand regulated forms of Cre have been increasingly used in these applications in order to gain temporal and spatial contr
Externí odkaz:
https://doaj.org/article/aaa5a2e6090e49d988e165e04f050513
Autor:
Anita D'Souza, Nina Shah, Cesar Rodriguez, Peter M. Voorhees, Katja Weisel, Orlando F. Bueno, Rajvineeth K. Pothacamury, Kevin J. Freise, Susan Yue, Jeremy A. Ross, Akshanth R. Polepally, Chetasi Talati, Shane Lee, Ziyi Jin, Ben Buelow, Ravi Vij, Shaji Kumar
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 40, iss 31
PURPOSE ABBV-383, a B-cell maturation antigen × CD3 T-cell engaging bispecific antibody, has demonstrated promising results in an ongoing first-in-human phase I study (ClinicalTrials.gov identifier: NCT03933735 ) in patients with relapsed/refractory
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1d490c0a00399fe00cc257aa6c8750b
https://doi.org/10.1200/jco.22.01504
https://doi.org/10.1200/jco.22.01504
Autor:
Jing-Zhou Hou, Ryan Jacobs, Seok-Goo Cho, Sumana Devata, Sameh Gaballa, Dok Hyun Yoon, Don A. Stevens, Jin Seok Kim, Ben Buelow, Ranjit Nair
Publikováno v:
Blood. 140:1474-1475
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e18dd5f428c3503e2324a53e65e98cd
https://doi.org/10.1182/blood-2022-166385
https://doi.org/10.1182/blood-2022-166385
Autor:
Myra R. Robinson, Peter M. Voorhees, Marina Leonidas, Manisha Bhutani, Katherine Rigby, Ami Ndiaye, James T. Symanowski, Nury Steuerwald, Duy Pham, Shebli Atrash, Ben Buelow, Elise Tjaden, Saad Z. Usmani, Barry Paul, Fei Guo, David M. Foureau
Publikováno v:
eJHaem. 1:113-121
TNB-383B is a fully human BCMA-targeting T-cell engaging bispecific monoclonal antibody (T-BsAb). We assessed ex vivo efficacy of this drug to mediate killing of bone marrow mononuclear cells (BMMCs) freshly isolated from 10 patients with relapsed mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ae91950cb5a6f06d0dd0859cc66b620
https://doi.org/10.1002/jha2.69
https://doi.org/10.1002/jha2.69
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.